Clinical trial data reveal a compelling statistic in the evolution of AML treatment: just two oral pills could replace the current standard of monthly intravenous therapy for elderly patients. The ASCERTAIN V Phase I/II trial demonstrates that this simplified oral combination—consisting of decitabine-cedazuridine and venetoclax—achieves response rates and survival outcomes equivalent to conventional IV regimens.
This finding carries substantial implications for treatment accessibility and patient adherence. Older adults with AML frequently face complications managing repeated hospital visits, including transportation challenges, appointment scheduling difficulties, and treatment-related fatigue. The oral formulation maintains therapeutic efficacy while dramatically simplifying the treatment logistics. For elderly patients where treatment burden significantly influences compliance and quality of life outcomes, this shift from injectable to oral administration represents a meaningful clinical advancement supported by rigorous trial evidence.
Read the full article on GMJ Newsroom.
Was this article helpful?
